M.D. Anderson Opens First-Ever IBC Clinic

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 12
Volume 15
Issue 12

The University of Texas M.D. Anderson Cancer Center has opened the first clinic in the world dedicated to the research and treatment of inflammatory breast cancer (IBC). The clinic, under the co-direction of Massimo Cristofanilli, MD, associate professor of breast medical oncology, and Thomas Buchholz, MD, professor of radiation oncology, is housed in the Nellie B. Connally Breast Center.

HOUSTON—The University of Texas M.D. Anderson Cancer Center has opened the first clinic in the world dedicated to the research and treatment of inflammatory breast cancer (IBC). The clinic, under the co-direction of Massimo Cristofanilli, MD, associate professor of breast medical oncology, and Thomas Buchholz, MD, professor of radiation oncology, is housed in the Nellie B. Connally Breast Center.

"Our primary goal is to finally understand why this disease is different, why it is so resistant to treatment, and ultimately to develop therapies that improve the well-being of women with this very rare form of breast cancer," Dr. Cristofanilli said. Inflammatory breast cancer represents just 1% to 2% of all breast cancers.

Already, M.D. Anderson sees approximately 30 new cases of IBC a year, more than any other institution in the country, Dr. Cristofanilli said. With the new clinic, he and his team hope to see 60 to 80 new cases annually.

He noted that PET scans may appear to allow better detection of the disease than mammography. He also pointed out that in early preliminary studies, lapatinib (Tykerb), a small-molecule inhibitor of EGFR and HER2, has shown promise for IBC patients whose tumors express HER2 (see ONI November 2006, page 2).

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content